Last reviewed 2026-04-19 · How we verify

LMN-201 Anti-toxin B VHH-3

Lumen Bioscience, Inc. · Phase 1 active Biologic

LMN-201 Anti-toxin B VHH-3 is a Biologic drug developed by Lumen Bioscience, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	LMN-201 Anti-toxin B VHH-3
Sponsor	Lumen Bioscience, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LMN-201 Anti-toxin B VHH-3 CI brief — competitive landscape report
LMN-201 Anti-toxin B VHH-3 updates RSS · CI watch RSS
Lumen Bioscience, Inc. portfolio CI

Frequently asked questions about LMN-201 Anti-toxin B VHH-3

What is LMN-201 Anti-toxin B VHH-3?

LMN-201 Anti-toxin B VHH-3 is a Biologic drug developed by Lumen Bioscience, Inc..

Who makes LMN-201 Anti-toxin B VHH-3?

LMN-201 Anti-toxin B VHH-3 is developed by Lumen Bioscience, Inc. (see full Lumen Bioscience, Inc. pipeline at /company/lumen-bioscience-inc).

What development phase is LMN-201 Anti-toxin B VHH-3 in?

LMN-201 Anti-toxin B VHH-3 is in Phase 1.

Manufacturer: Lumen Bioscience, Inc. — full pipeline
Compare: LMN-201 Anti-toxin B VHH-3 vs similar drugs
Pricing: LMN-201 Anti-toxin B VHH-3 cost, discount & access